Cutler Group’s Arcus Biosciences RCUS Stock Holding History

Cutler Group’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-51,100	Closed	-$24K	–	5401
2022 Q2	$24K	Buy	51,100 +50,000	+4,545%	+$1.22M	﹤0.01%	2527
2022 Q1	$7K	Buy	+1,100	New	+$36.9K	﹤0.01%	3908

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cutler Group's RCUS Position: Q3 2023 in Review

Cutler Group sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 1,200 shares — an estimated $24.1K sold.

Cutler Group first reported a position in RCUS in Q1 2020 and held it in 12 quarters. The position peaked at $132K in Q2 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Cutler Group reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 1,200 Arcus Biosciences shares in Q3 2023, an estimated $24.1K.
Cutler Group first reported a position in Arcus Biosciences in Q1 2020 and held it in 12 quarters.
Cutler Group's Arcus Biosciences position peaked at $132K in Q2 2022.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.